Diabetes MellitusNOMADNCT05913726
MDT Conferences for People With Diabetes and Multimorbidity
An observational study of Diabetes Mellitus and Comorbidities and Coexisting Conditions, run by Odense University Hospital at 1 site in Denmark.
Trial summary
The goal of this observational study is to test if regular meetings (multidisciplinary team conferences) between several different medical doctors can work well in everyday hospital life. The doctor meetings are meant to discuss patients who have both diabetes and other chronic conditions at the same time. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus, Comorbidities and Coexisting Conditions
- How many people
- 55 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Aug 2023to 1 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Study population consists of all adult residents in the geographical region of Funen, Denmark, who meet eligibility criteria. Funen inhabits approximately 500.000.
Who may be able to join
- Adult, any type of diabetes, diabetes management by general practitioner or Steno Diabetes Centre Odense, minimum one chronic condition within heart, kidney or lung specialities.
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Network of Doctors for Multimorbidity and Diabetes - The NOMAD Intervention: Protocol for Feasibility Trial of Multidisciplinary Team Conferences for People With Diabetes and Multimorbidity
The goal of this observational study is to test if regular meetings (multidisciplinary team conferences) between several different medical doctors can work well in everyday hospital life. The doctor meetings are meant to discuss patients who have both diabetes and other chronic conditions at the same time.
The main questions it aims to answer are:
Read more
- How can the concept of these meetings work in everyday hospital life?
- What are the patients and doctors getting out of the meetings?
Patients with diabetes and concurrent other diseases will be asked:
- if they want their case discussed on the doctor meeting
- to answer a set of questions about their well-being and symptoms before and 6 months after the meeting
- if the research group can store their information for the study
Doctors participating in the meetings are asked to answer questions about what they have learned in the meetings.
Read the detailed description
Introduction: Many people struggle with several chronic conditions at once. This is known as multimorbidity. The prevalence of multimorbidity is rising. Diabetes is one of the chronic conditions often associated with multimorbidity. The prevalence of diabetes is likewise increasing world-wide.
Having diabetes and multimorbidity can be a great burden for a person as they have to deal with symptoms, treatments, lifestyle changes and checkups. The picture complicates as many healthcare systems have a disease-specific approach rather than a patient-centered approach. This often leads to multiple different outpatient clinic contacts, possibly uncoordinated treatment and fragmented care. One can view the patient as a nomad between departments and sectors, often lacking coherence.
The aim of this study is to feasibility test a complex intervention designed to coordinate care and treatment for people with diabetes and multimorbidity prior to a large-scale randomised trial.
Intervention: To gain a more patient-centered approach, better coordination of care and treatment and possibly increase life quality for people with diabetes and multimorbidity, a working group has set out to develop a complex intervention guided by relevant guidelines. The intervention consists of multidisciplinary team conferences (MDT) performed by medical doctors within the specialities of endocrinology, cardiology, respiratory medicine, nephrology and clinical pharmacology, called Network of dOctors for Multimorbidity and Diabetes - NOMAD. The doctors sit together every two weeks to discuss the treatment, coordinate care and review medications of referred patients with diabetes and minimum one other condition within the collaborating specialities. Patients can be referred from hospital departments or from their general practitioner (GP), in which case, the GP attends the meeting by video conference. Prior to the MDT, a questionnaire concerning health related quality of life is sent out to the patient. The same questionnaire is sent out 6 months after the MDT and followed by a contact to the patient - either physical or by phone by healthcare professional. The doctors review the answers before the MDT and use them as discussion support in the MDT. All doctors attending the MDT have time scheduled prior to MDT to prepare and read about the patients. Especially the clinical pharmacologist has extended preparation time to ensure a thorough review of the patients medications list - which oftentimes consist of more than 15 different prescriptions.
Methods: This is a one-arm mixed-methods feasibility study of a complex intervention. The MDT conferences will be evaluated for feasibility through prospectively collected data. The evaluation will be based on the following process indicators:
- completion of PRO-questionnaire
- technical issues before, during or after MDT
- time schedule in MDT kept or not
- does MDT conclusion note correspond to MDT referral letter?
- clinician preparation time
The patients' perspectives will be explored through the questionnaires and also through interviews of a selection of participants - both intervention receivers and providers, contributing to a qualitative process evaluation. The feasibility of using (patient-reported outcome, PRO) a collection of generic, validated questionnaires to measure intervention effect will be assessed. Through a run-time of 17 months, approximately 120 participants are anticipated. Results will be reported narratively and with descriptive statistics. The interviews will be reported in a separate paper.
Ethics: As the study focuses mainly on an organisational level, detailed information on individual level is not required. The scientific ethics committee has been requested for approval, replying that this study is exempt from ethics approval as it collects no human material (ref. number: 20222000 - 150).
The study is registered in list of research/quality-development projects in Region of Southern Denmark (ref. number: 22/56265).
Implications: This study will provide valuable insights into how a complex intervention of MDTs can be implemented in clinical practice, how it is received by end-users and provide decision-makers with useful experience on how to organise such an intervention. Furthermore it will elucidate the use of PRO and laboratory values as effect measures. All of this will lay the grounds for a future randomised trial where efficiency, effectiveness and clinical effect of MDT can be evaluated.
- Keywords
- Multidisciplinary team conferences, Feasibility
- Medical subject headings
- Diabetes Mellitus
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment
Number of patients referred to MDT. Reported as total number of referred patients throughout the project period and as mean/median per MDT.
Measured: Full project period, 17 months.
Completion of PRO-questionnaire
How many participants completed the PRO-questionnaire. Reported as absolute number and percentage of total number of participants.
Measured: Full project period, 17 months.
Technical difficulties i relation to MDT
How many times did technical difficulties occur i relation to MDT. Technical difficulties defined as 1) problem with sending/receiving referral letter, 2) managing PRO-questionnaire completion, 3) problems with video, sound or connection during MDT or 4) problems with contacting participant for followup. Reported as absolute numbers and percentage of all MDTs.
Measured: Full project period, 17 months.
Time schedule
Was time schedule kept on MDT? Simple count of how often time schedule of 30 minutes per patient case was NOT kept. Reported as absolute number and percentage of total number of patient cases.
Measured: Full project period, 17 months.
MDT recommendations
How often are MDT recommendations initiated? Assessed at 6 month follow up by examining electronic patient records and conversation with participant. Reported as simple count of how many times recommendations are followed/initiated and percentage of recommendations followed out of total MDT recommendations.
Measured: Assessed at 6 month follow up.
Clinician preparation time
How many minutes does each clinician take to prepare an MDT case discussion? Assessed by survey completed by clinicians at end of each MDT case discussion. Reported as means and medians in whole minutes.
Measured: Full project period, 17 months.
Secondary outcomes (2)
Laboratory values
A simple count of how many participants who have relevant laboratory values (HbA1C, LDL, creatinine) less than 90 days old at time point of referral and time point of 6 months follow up. Reported as absolute numbers and percentages.
Measured: Assessed at time point of referral to MDT and 6 months after MDT.
Clinician learning
To which degree did the clinician find the MDT case discussion educational/enlightening/useful for personal development? Assessed by completion of mini-survey by each clinician at the end of each MDT case discussion. Survey consists of visual analogue scale 0-100 mm. 0 indicating "not educational at all" and 100 indicating "most educational, as much as possible". Clinician learning is reported as means and medians on this scale.
Measured: Full project period, 17 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2023
- Study start1 Aug 2023
- Primary completion30 Jun 2025
- Study completion1 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Odense University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- Odense University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Steno Diabetes Center Odense
- Responsible party
- Principal investigator, Stine Jorstad Bugge, Odense University Hospital
- Investigators
- Ann-Dorthe O Zwisler, Professor, Principal investigator, Dept.s of Cardiology and Clinical Research, O.U. Hospital and University of Southern Denmark.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05913726
- Sponsor's protocol ID
- Steno-MDT3
- Acronym
- NOMAD
- Status last verified
- Dec 2025
- First submitted
- 26 Apr 2023
- Last updated
- 9 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The results will be published and shared in an international peer-reviewed journal.
Publications
Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract. 2008;14 Suppl 1:28-32. doi: 10.1080/13814780802436093.
PubMed 18949641Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
PubMed 31518657Williams JS, Egede LE. The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability. Am J Med Sci. 2016 Jul;352(1):45-52. doi: 10.1016/j.amjms.2016.03.004. Epub 2016 Mar 18.
PubMed 27432034Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061.
PubMed 34593508O'Cathain A, Croot L, Duncan E, Rousseau N, Sworn K, Turner KM, Yardley L, Hoddinott P. Guidance on how to develop complex interventions to improve health and healthcare. BMJ Open. 2019 Aug 15;9(8):e029954. doi: 10.1136/bmjopen-2019-029954.
PubMed 31420394Henriksen DP, Ennis ZN, Panou V, Hangaard J, Jensen PB, Johansson SL, Nagarajah S, Poulsen MK, Rothmann MJ, Schousboe K, Bugge SJ, Jessen LB, Schneider IR, Olsen Zwisler AD, Hojlund K, Damkier P. Physician-led in-hospital multidisciplinary team conferences with multiple medical specialities present - A scoping review. J Multimorb Comorb. 2022 Dec 7;12:26335565221141745. doi: 10.1177/26335565221141745. eCollection 2022 Jan-Dec.
PubMed 36518524Andersen JD, Jensen MH, Vestergaard P, Jensen V, Hejlesen O, Hangaard S. The multidisciplinary team in diagnosing and treatment of patients with diabetes and comorbidities: A scoping review. J Multimorb Comorb. 2023 Mar 20;13:26335565231165966. doi: 10.1177/26335565231165966. eCollection 2023 Jan-Dec.
PubMed 36968789Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes. 2004 Sep 20;2:51. doi: 10.1186/1477-7525-2-51.
PubMed 15380021Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol. 2001 Jul;54(7):680-6. doi: 10.1016/s0895-4356(00)00368-1.
PubMed 11438408Bugge SJ, Henriksen DP, Damkier P, Rahbek MT, Schousboe K, Rothmann MJ, Poulsen MK, Hansen C, Nagarajah S, Jensen PB, Johansson SL, Panou V, Schneider IR, Pedersen CG, Andersen JD, Hangaard J, Zwisler AO. Network of doctors for multimorbidity and diabetes - the NOMAD intervention: protocol for feasibility trial of multidisciplinary team conferences for people with diabetes and multimorbidity. Pilot Feasibility Stud. 2024 Jun 15;10(1):91. doi: 10.1186/s40814-024-01517-0.
PubMed 38879561
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Network of Doctors for Multimorbidity and Diabetes - The NOMAD Intervention: Protocol for Feasibility Trial of Multidisciplinary Team Conferences for People With Diabetes and Multimorbidity
- ClinicalTrials.gov ID
- NCT05913726
- Acronym / sponsor ID
- NOMAD / Steno-MDT3
- Keywords
- Multidisciplinary team conferences, Feasibility
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- Odense University HospitalUniversity, hospital or other
- Collaborators
- Steno Diabetes Center Odense
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 1 Jul 2025 (actual)
- First posted
- 22 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to test if regular meetings (multidisciplinary team conferences) between several different medical doctors can work well in everyday hospital life. The doctor meetings are meant to discuss patients who have both diabetes and other chronic conditions at the same time.
The main questions it aims to answer are:
- How can the concept of these meetings work in everyday hospital life?
- What are the patients and doctors getting out of the meetings?
Patients with diabetes and concurrent other diseases will be asked:
- if they want their case discussed on the doctor meeting
- to answer a set of questions about their well-being and symptoms before and 6 months after the meeting
- if the research group can store their information for the study
Doctors participating in the meetings are asked to answer questions about what they have learned in the meetings.
Detailed description
Introduction: Many people struggle with several chronic conditions at once. This is known as multimorbidity. The prevalence of multimorbidity is rising. Diabetes is one of the chronic conditions often associated with multimorbidity. The prevalence of diabetes is likewise increasing world-wide.
Having diabetes and multimorbidity can be a great burden for a person as they have to deal with symptoms, treatments, lifestyle changes and checkups. The picture complicates as many healthcare systems have a disease-specific approach rather than a patient-centered approach. This often leads to multiple different outpatient clinic contacts, possibly uncoordinated treatment and fragmented care. One can view the patient as a nomad between departments and sectors, often lacking coherence.
The aim of this study is to feasibility test a complex intervention designed to coordinate care and treatment for people with diabetes and multimorbidity prior to a large-scale randomised trial.
Intervention: To gain a more patient-centered approach, better coordination of care and treatment and possibly increase life quality for people with diabetes and multimorbidity, a working group has set out to develop a complex intervention guided by relevant guidelines. The intervention consists of multidisciplinary team conferences (MDT) performed by medical doctors within the specialities of endocrinology, cardiology, respiratory medicine, nephrology and clinical pharmacology, called Network of dOctors for Multimorbidity and Diabetes - NOMAD. The doctors sit together every two weeks to discuss the treatment, coordinate care and review medications of referred patients with diabetes and minimum one other condition within the collaborating specialities. Patients can be referred from hospital departments or from their general practitioner (GP), in which case, the GP attends the meeting by video conference. Prior to the MDT, a questionnaire concerning health related quality of life is sent out to the patient. The same questionnaire is sent out 6 months after the MDT and followed by a contact to the patient - either physical or by phone by healthcare professional. The doctors review the answers before the MDT and use them as discussion support in the MDT. All doctors attending the MDT have time scheduled prior to MDT to prepare and read about the patients. Especially the clinical pharmacologist has extended preparation time to ensure a thorough review of the patients medications list - which oftentimes consist of more than 15 different prescriptions.
Methods: This is a one-arm mixed-methods feasibility study of a complex intervention. The MDT conferences will be evaluated for feasibility through prospectively collected data. The evaluation will be based on the following process indicators:
- completion of PRO-questionnaire
- technical issues before, during or after MDT
- time schedule in MDT kept or not
- does MDT conclusion note correspond to MDT referral letter?
- clinician preparation time
The patients' perspectives will be explored through the questionnaires and also through interviews of a selection of participants - both intervention receivers and providers, contributing to a qualitative process evaluation. The feasibility of using (patient-reported outcome, PRO) a collection of generic, validated questionnaires to measure intervention effect will be assessed. Through a run-time of 17 months, approximately 120 participants are anticipated. Results will be reported narratively and with descriptive statistics. The interviews will be reported in a separate paper.
Ethics: As the study focuses mainly on an organisational level, detailed information on individual level is not required. The scientific ethics committee has been requested for approval, replying that this study is exempt from ethics approval as it collects no human material (ref. number: 20222000 - 150).
The study is registered in list of research/quality-development projects in Region of Southern Denmark (ref. number: 22/56265).
Implications: This study will provide valuable insights into how a complex intervention of MDTs can be implemented in clinical practice, how it is received by end-users and provide decision-makers with useful experience on how to organise such an intervention. Furthermore it will elucidate the use of PRO and laboratory values as effect measures. All of this will lay the grounds for a future randomised trial where efficiency, effectiveness and clinical effect of MDT can be evaluated.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Study population consists of all adult residents in the geographical region of Funen, Denmark, who meet eligibility criteria. Funen inhabits approximately 500.000.
Key inclusion criteria (1 listed)
- Adult, any type of diabetes, diabetes management by general practitioner or Steno Diabetes Centre Odense, minimum one chronic condition within heart, kidney or lung specialities.
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Recruitment
Time frame: Full project period, 17 months.
Number of patients referred to MDT. Reported as total number of referred patients throughout the project period and as mean/median per MDT.
Completion of PRO-questionnaire
Time frame: Full project period, 17 months.
How many participants completed the PRO-questionnaire. Reported as absolute number and percentage of total number of participants.
Technical difficulties i relation to MDT
Time frame: Full project period, 17 months.
How many times did technical difficulties occur i relation to MDT. Technical difficulties defined as 1) problem with sending/receiving referral letter, 2) managing PRO-questionnaire completion, 3) problems with video, sound or connection during MDT or 4) problems with contacting participant for followup. Reported as absolute numbers and percentage of all MDTs.
Time schedule
Time frame: Full project period, 17 months.
Was time schedule kept on MDT? Simple count of how often time schedule of 30 minutes per patient case was NOT kept. Reported as absolute number and percentage of total number of patient cases.
MDT recommendations
Time frame: Assessed at 6 month follow up.
How often are MDT recommendations initiated? Assessed at 6 month follow up by examining electronic patient records and conversation with participant. Reported as simple count of how many times recommendations are followed/initiated and percentage of recommendations followed out of total MDT recommendations.
Clinician preparation time
Time frame: Full project period, 17 months.
How many minutes does each clinician take to prepare an MDT case discussion? Assessed by survey completed by clinicians at end of each MDT case discussion. Reported as means and medians in whole minutes.
2 secondary outcomes
Laboratory values
Time frame: Assessed at time point of referral to MDT and 6 months after MDT.
Clinician learning
Time frame: Full project period, 17 months.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2025.
- Background: PubMed 18949641Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract. 2008;14 Suppl 1:28-32. doi: 10.1080/13814780802436093.
- Background: PubMed 31518657Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.
- Background: PubMed 27432034Williams JS, Egede LE. The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability. Am J Med Sci. 2016 Jul;352(1):45-52. doi: 10.1016/j.amjms.2016.03.004. Epub 2016 Mar 18.
- Background: PubMed 34593508Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, Boyd KA, Craig N, French DP, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. BMJ. 2021 Sep 30;374:n2061. doi: 10.1136/bmj.n2061.
- Background: PubMed 31420394O'Cathain A, Croot L, Duncan E, Rousseau N, Sworn K, Turner KM, Yardley L, Hoddinott P. Guidance on how to develop complex interventions to improve health and healthcare. BMJ Open. 2019 Aug 15;9(8):e029954. doi: 10.1136/bmjopen-2019-029954.
- Background: PubMed 36518524Henriksen DP, Ennis ZN, Panou V, Hangaard J, Jensen PB, Johansson SL, Nagarajah S, Poulsen MK, Rothmann MJ, Schousboe K, Bugge SJ, Jessen LB, Schneider IR, Olsen Zwisler AD, Hojlund K, Damkier P. Physician-led in-hospital multidisciplinary team conferences with multiple medical specialities present - A scoping review. J Multimorb Comorb. 2022 Dec 7;12:26335565221141745. doi: 10.1177/26335565221141745. eCollection 2022 Jan-Dec.
- Background: PubMed 36968789Andersen JD, Jensen MH, Vestergaard P, Jensen V, Hejlesen O, Hangaard S. The multidisciplinary team in diagnosing and treatment of patients with diabetes and comorbidities: A scoping review. J Multimorb Comorb. 2023 Mar 20;13:26335565231165966. doi: 10.1177/26335565231165966. eCollection 2023 Jan-Dec.
- Background: PubMed 15380021Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes. 2004 Sep 20;2:51. doi: 10.1186/1477-7525-2-51.
- Background: PubMed 11438408Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJ, Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol. 2001 Jul;54(7):680-6. doi: 10.1016/s0895-4356(00)00368-1.
- Derived from this study: PubMed 38879561Bugge SJ, Henriksen DP, Damkier P, Rahbek MT, Schousboe K, Rothmann MJ, Poulsen MK, Hansen C, Nagarajah S, Jensen PB, Johansson SL, Panou V, Schneider IR, Pedersen CG, Andersen JD, Hangaard J, Zwisler AO. Network of doctors for multimorbidity and diabetes - the NOMAD intervention: protocol for feasibility trial of multidisciplinary team conferences for people with diabetes and multimorbidity. Pilot Feasibility Stud. 2024 Jun 15;10(1):91. doi: 10.1186/s40814-024-01517-0.
- World Health Organization. Multimorbidity. Geneva. ; 2016. ISBN 978-92-4-151165-0Link provided by the sponsor.
- Invisible numbers: the true extent of noncommunicable diseases and what to do about them. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.Link provided by the sponsor.
- Individual participant dataSharing planned: No. The results will be published and shared in an international peer-reviewed journal.
Related trials for Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ann-Dorthe O Zwisler, Professor principal investigator
Dept.s of Cardiology and Clinical Research, O.U. Hospital and University of Southern Denmark.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus and Comorbidities and Coexisting Conditions, run by Odense University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment (time frame: Full project period, 17 months.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05913726, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2025.